PATENT CLAIM ANALYSIS

Application Number: 15749322
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "299000"]

Abstract:
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Claim (Index 25):
The method of  claim 24 , wherein the disease or disorder is selected from asthma, atopic dermatitis, acne, Crohn's disease, regional enteritis, ulcerative colitis, Sj\u00f6gren's syndrome, uveitis, Beh\u00e7et's disease, dermatomyositis, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, psoriasis, psoriatic arthritis (PsA), steroid resistant asthma, and rheumatoid arthritis.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 86.0
- Lexical Diversity: 1.54762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14933468', '15455481', '14990430', '14609798', '14888129']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8735563560302927
- 35 USC 102 Novelty (BERT): 0.5672029747049897
- Combined Prediction Score: 0.8429210178977624
- Mean Citation Score: 451.417868
- Max Citation Score: 455.46802
- Similarity Product: 320.09066971418383

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test